Evidence map›Paper›PMID 41704375›Full record

ArticleACS medicinal chemistry letters2026

Synthesis and Biological Evaluation of a Novel Dual-Targeting Small Molecule Drug Conjugate Modulating the Crosstalk between α5β1 Integrin and MDM2 in Glioblastoma.

Federico Arrigoni, Ana Ferrari, Helena Prpić, Elena Markeviciute, Alessia Muzi, Giuseppe Roscilli, Silvia Gazzola, Umberto Piarulli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Federico ArrigoniDepartment of Science and High Technology Università degli Studi dell'Insubria, Via Valleggio 11, Como 22100, Italy.
Ana FerrariA. Ferrari, A. Muzi, and Dr. G. Roscilli Takis s.r.l., Via Castel Romano 100, 00128 Rome, Italy.
Helena PrpićDepartment of Science and High Technology Università degli Studi dell'Insubria, Via Valleggio 11, Como 22100, Italy.
Elena MarkeviciuteDepartment of Science and High Technology Università degli Studi dell'Insubria, Via Valleggio 11, Como 22100, Italy.
Alessia MuziA. Ferrari, A. Muzi, and Dr. G. Roscilli Takis s.r.l., Via Castel Romano 100, 00128 Rome, Italy.
Giuseppe RoscilliA. Ferrari, A. Muzi, and Dr. G. Roscilli Takis s.r.l., Via Castel Romano 100, 00128 Rome, Italy.
Silvia GazzolaDepartment of Science and High Technology Università degli Studi dell'Insubria, Via Valleggio 11, Como 22100, Italy.ORCID https://orcid.org/0000-0001-6745-3598
Umberto PiarulliDepartment of Science and High Technology Università degli Studi dell'Insubria, Via Valleggio 11, Como 22100, Italy.ORCID https://orcid.org/0000-0002-6952-1811

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Negative crosstalk between α5β1 integrin and the p53-MDM2 regulatory axis contributes to glioblastoma progression and therapeutic resistance. To explore the potential of dual inhibition of these two biological targets, the dual targeting small molecule drug conjugate (SMDC) (

Indexed as

cross-talkdrug conjugatedual-targeting SMDCglioblastomaMDM2 inhibitorp53α5β1 integrin

Identifiers

PMID41704375
PMCPMC12907918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.